Novartis is restructuring

The Swiss drug manufacturer Novartis will conduct a significant restructuring of the product portfolio, which includes many business sale and acquisition of a division of the British company GlaxoSmithKline (GSK) in a series of transactions totaling over $25 billion.

Novartis announced on Tuesday that it will take the cancer drugs division of GSK for about $14.5 billion, says the Wall Street Journal.

Also, the Novartis Vaccines British company is selling operations for $5.25 billion.

Both transactions include provisions for future payments based on the achievement of future targets, which could increase the final price.